CNBC's Jim Cramer reports on the latest news regarding Moderna. 'Mad Money' host Jim Cramer looks at the recent move down in ...

HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share ...

Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.

In addition to Berenberg Bank, Moderna also received a Hold from HSBC’s Yifeng Liu in a report issued yesterday. However, on the same day, Piper Sandler maintained a Buy rating on Moderna (NASDAQ: ...

On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $39.77 which represents a decrease of $-2.37 or -5.62% from the prior close of $42.14. The stock opened at $42.05 and touched a ...

On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.29 which represents a decrease of $-0.25 or -0.47% from the prior close of $53.54. The stock opened at $53.53 and touched a ...

Live Updates Stocks on the Move Today 9:49 am Here are some notable stocks on the move today: Super Micro Computer: The ...

That includes Big Tech, which is currently making a series of peculiar investments in a few strange companies. This has nothing to do with tech. At least on the surface … Yet, these strange ...

Leerink Partners reduced their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. HSBC raised Moderna ...